Abstract
UICC classification accurately predicts overall survival but not recurrence-risk. We report here data of overall and first site-specific recurrence following curative surgery useful for the development of recurrence-oriented preventive target therapies. Patients who underwent resection for gastric cancer were stratified according to curability of surgery [curative (R0) vs non-curative resection], extent of surgery [limited (D1) vs extended (D2) node dissection] and pathological nodal/serosal status. The intent-to-treat principle, log-rank test and Cox regression analysis were used for statistical analysis of time-to-event (recurrence, death) endpoints. Curative resection only produced a chance of cure whereas survival was very poor following non-curative resection (P < 0.0001). For D2 R0 subgroup of patients, a pathological serosa and a node state-based classification into three groups, proved to be of clinical implication. Risk of recurrence after a median follow-up of 92 months was low among patients with both serosa and node-negative cancer (first group; 11%), moderate among those with either serosa or node-positive cancer (second group; 53%) and very high among those with both serosa and node-positive cancer (third group; 83%). In multivariate analysis, the relative risks of recurrence and death from gastric cancer among patients in the second and third groups, as compared to those in the first, were 7.07 (95% CI, 2.36–21.17; P = 0.0002) and 16.19 (95% CI, 5.76–45.54; P < 0.0001) respectively. First site-specific recurrence analysis revealed: low rate of loco-regional recurrence alone (12%), serosa state determinant factor of the site-recurrence (peritoneal for serosa-positive and haematogenous for serosa-negative cancers) and dramatic increase of all types of recurrence by the presence of nodal metastases. Our findings demonstrate that a pathological serosa- and node-based classification is very simple and predicts accurately site-specific recurrence-risks. Furthermore they reveal that risk of recurrence following curative D2 surgery alone is low for serosa- and node-negative cancers, but very high in serosa- and node-positive cancers suggesting the need for new therapeutic strategies in this subgroup of patients. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Averbach AM and Jacquet P (1996) Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 83: 726–733
Bearhs OH, Henson DE, Hutter RVP and Kennedy BJ (eds) (1992) Manual for staging. American Joint Committee on Cancer, Philadellphia JB: Lippincott
Bonenkamp JJ, Hermans J, Sasako M and van de Velde CJH (1999) Extended lymph-node dissection for gastric cancer. N Engl J Med 340: 908–914
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G and Schlimok G (2000) Cytoceratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525–533
Brennan MF (1999) Lymph-node dissection for gastric cancer. N Engl J Med 340: 956–958, (editorial)
Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GJ and Bruijn JA (1995) Surgical/pathologic-stage migration confounds comparison of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13: 19–25
Cox DR (1972) Regression models and life tables. J R Stat Soc [B] 34: 187–220
Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M and Fayers P (1999) Patient survival after D1 and D2 resection for gastric cancer: long-term results of the MRC randomised surgical trial. Surgical co-operation group. Br J Cancer 79: 1522–1530
Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M and Van de Velde CJ (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11: 1441–1447
Fujii M, Sasaki J and Nakajima T (1999) State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer 2: 151–157
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kim JP (1999) Surgical results with immunochemotherapy. Kim JP, Min JS, Mok YJ eds. Proceedings of the 3rd International Gastric Cancer Congress, Seoul 1999. Monduzzi Editore, Bologna (Italy), pp. 3–9
Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y and Sugimachi K (2000) Postoperative outcomes of sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87: 353–357
Marujama K, Okabayashi K and Kinoshita T (1987) Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 11: 418–425
Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K and Goto M and the Gastric Cancer Surgical Study Group (1999) Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomized trial. Lancet 354: 273–277
Nishi M, Omori Y and Miwa K (1995) Japanese classification of gastric carcinoma. Japanese Research Society for Gastric Cancer (JRSGC), Tokyo, Kanehara & Co.
Roukos DH (2000a) Current status and future perspectives in gastric cancer management. Cancer Treat Rev 26: 243–255, Review
Roukos DH (2000b) Extended (D2) lymph node dissection for gastric cancer: do patients benefit?. Ann Surg Oncol 7: 253–255, (editorial)
Roukos D, Hottenrott C, Lorenz M and Koutsogiorgas-Couchell S (1990) A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. J Cancer Res Clin Oncol 116: 307–313
Roukos DH, Lorenz M and Encke A (1998) Evidence of survival benefit of extended lymphadenectomy in Western gastric cancer patients based on a new concept. A prospective long-term follow-up study. Surgery 123: 573–578
Roukos DH, Paraschou P and Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7: 719–726
Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB and Richardson WS (1996) Evidence based medicine: what it is and what it isn't. BMJ 312: 71
Siewert JR, Boettcher K, Stein HJ and Roder JD (1998) Relevant prognostic factors in gastric cancer. Ten-year results of the German Gastric cancer Study. Ann Surg 228: 449–461
The Lancet (Editorial) (2000) Overoptimisims about cancer. Lancet 355: 157
Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Winchester and Osteen R (1993) Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 218: 583–587
Zippelius A and Pantel K (2000) RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci 20: 110–123
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Roukos, D., Lorenz, M., Karakostas, K. et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: A prospective with quality control 10-year follow-up study. Br J Cancer 84, 1602–1609 (2001). https://doi.org/10.1054/bjoc.2001.1720
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1720
Keywords
This article is cited by
-
Differences in risk factors between patterns of recurrence in patients after curative resection for advanced gastric carcinoma
World Journal of Surgical Oncology (2013)
-
Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute
Surgical Endoscopy (2012)
-
Outweighing the benefits and weakness of endoscopic submucosal dissection for early gastric cancer in the west
Surgical Endoscopy (2010)
-
Robotic versus laparoscopic gastrectomy
Surgical Endoscopy (2010)
-
Open versus laparoscopic versus robotic gastrectomy for cancer: need for comparative-effectiveness quality
Surgical Endoscopy (2010)